Skip to content
Clinical Trials – home
DenmarkBack to Denmark

Clinical trials in Koege

1 198 clinical trials in Koege, Denmark across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Koege at a glance
1 198
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 198 trials in Koege

Open in trial search

Obesity+1

Recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Osteoarthritis

Recruiting

Efficacy of intra‑articular allogeneic peripheral blood mononuclear cells induced to an early apoptotic state versus placebo in adults with primary knee osteoarthritis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Peripheral Blood Mononuclear Cells Induced To An Early Apoptotic State
  • Sponsor:Enlivex Therapeutics Ltd.

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Ribocure Pharmaceuticals AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Other cities in Denmark

The busiest research cities in the country

All 45 cities in Denmark

Clinical research in Koege

What the registry says about research in the country

01 Cardiovascular and Emergency Care Research

Clinical trials in Køge are exploring cardiovascular diseases and acute care, with a focus on improving outcomes for patients with hypotension and shock. These studies are designed to test new treatment approaches that may help stabilize patients faster and reduce the need for intensive care.

  • Early treatment strategies for low blood pressure and shock
  • New approaches to reduce cardiovascular risk
  • Supportive care for emergency department patients

The research reflects a strong interest in faster, more effective care for serious circulatory conditions.

02 Diabetes and Metabolic Disease Studies

Several trials are centered on type 1 diabetes and related nutritional and metabolic diseases, including efforts to lower long-term cardiovascular complications. The research is aimed at testing whether more intensive care strategies and new treatment options can improve health outcomes for people living with diabetes.

  • Intensified care for people with type 1 diabetes at high cardiovascular risk
  • Evaluating protective treatment options for heart-related complications
  • Improving long-term disease control in diabetes

These studies combine prevention and treatment research to support better chronic disease management.

03 Bone, Joint, and Musculoskeletal Research

Research in musculoskeletal diseases includes trials for diabetic acute Charcot foot, a serious complication that can affect mobility and bone health. The main purpose is to evaluate whether a new treatment approach can improve healing and protect patients from further damage.

  • Treatment options for acute Charcot foot in diabetes
  • Restoring function and reducing complications
  • Clinical outcomes in diabetic foot care

This area of research is especially important for preserving movement and quality of life.

04 Ear, Nose, and Throat Research

Trials in otorhinolaryngologic diseases are focusing on chronic rhinosinusitis with nasal polyps, also known as CRSwNP. These studies are assessing whether patients who have responded well to biologic treatment can safely reduce or stop therapy without symptoms returning.

  • Long-term management of nasal polyps
  • Testing the durability of biologic treatment responses
  • Reducing treatment burden while maintaining disease control

This research aims to make care more tailored for people with persistent sinus disease.

05 Digestive System and Gastrointestinal Research

Clinical trials in digestive system diseases are investigating bile acid diarrhoea, with the goal of improving stool consistency and overall symptom control. The studies are evaluating whether a new tablet formulation can provide meaningful relief compared with placebo.

  • Symptom control in bile acid diarrhoea
  • Testing a new treatment for better bowel function
  • Improving quality of life for patients with chronic diarrhoea

These trials focus on practical treatment benefits that matter in everyday care.

06 Hormonal and Chronic Disease Care

Trials linked to hormonal diseases are also part of the research landscape, especially through studies involving diabetes-related complications and broader chronic disease management. The aim is to better understand how targeted therapies can support patients with complex, long-term conditions.

  • Chronic disease control in people with endocrine-related conditions
  • Supporting safer treatment strategies
  • Exploring therapies that may improve long-term outcomes

In Køge, this area connects closely with ongoing diabetes research and prevention-focused care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.